CJC-1295 vs Ipamorelin: Research Profile Comparison
CJC-1295 and Ipamorelin are commonly discussed together in growth-hormone-axis research because they act on different receptors within the same pathway. They are not the same class of compound.
| CJC-1295 | Ipamorelin | |
|---|---|---|
| Class | Growth hormone-releasing hormone (GHRH) analogue | Growth hormone secretagogue (ghrelin/GHS-R1a receptor agonist) |
| Receptor target | GHRH receptor | Ghrelin receptor (GHS-R1a) |
| Selectivity (research literature) | Reported to stimulate GH release with limited effect on other pituitary hormones | Reported as one of the more receptor-selective secretagogues studied, with limited reported effect on cortisol or prolactin in preclinical work |
| Regulatory note | On the WADA Prohibited List; no MHRA/UK marketing authorisation — see our legal-status page | On the WADA Prohibited List; no MHRA/UK marketing authorisation — see our legal-status page |
Takeaway
They act on two different receptors within the same growth-hormone-release pathway rather than being alternative versions of the same mechanism, which is why research literature frequently studies them together rather than as substitutes for one another.
Research-profile comparison for laboratory reference only — not a usage, dosing, or stacking guide. See our legal & compliance hub for the regulatory position on either compound.